A History of Serum Therapy: Methods
From The Long Sepsis, an encyclopedia of a world that didn't happen
Serum therapy is the medical treatment of bacterial infection through passive immunization using disease-fighting proteins harvested from the blood of animals immunized against specific pathogens. The practice originated in the late nineteenth century, emerged as the primary systemic response to bacterial infection after chemical antimicrobials proved insufficient, and remains the clinical foundation of infection treatment into the present.
The foundational method derives from work begun in the 1890s. Émile Roux and colleagues at the Pasteur Institute demonstrated that animals immunized against bacterial toxins produced proteins in their blood that could neutralize those same toxins when transferred to infected patients. The diphtheria antitoxin, developed from this principle and first administered to a patient in 1894, established both the biological mechanism and the clinical protocol: harvest serum from hyperimmunized horses, measure its potency against the target toxin, and inject it into the patient in doses calculated to overwhelm the pathogenic load. This method saved lives in diphtheria cases and remained, for decades, the only systemic treatment for toxin-mediated bacterial disease.
The limitation was specificity. Antitoxin worked only against toxins—the soluble poisons produced by certain bacteria—not against the bacteria themselves. When the azo drugs appeared in the 1930s as the first chemical class to kill bacteria systemically, antitoxin receded to its narrow domain. It remained standard for diphtheria, scarlet fever, and tetanus, where toxin was the primary pathological agent. But for septicaemia, for bacteraemia, for the overwhelming majority of life-threatening infections, the azo drugs appeared to be the future.
That assumption proved wrong. The 1943 Sicily campaign revealed the scale of the problem. Wounded soldiers treated with azo drugs still developed gangrene and septicaemia at rates close to pre-chemical era levels. The drugs were not reliably reaching infected tissue, or bacteria were surviving them, or both. By 1945, military medicine faced a crisis: the only systemic antibacterial agents available were failing in field conditions, and nothing else existed.
The response was containment. The Bacillary Congress of Geneva in 1952 formalized asepsis maximalism—the coordinated international doctrine that infection must be prevented rather than cured, because cure had failed. But prevention alone could not save patients already infected. Some systemic treatment was still necessary. Research institutions turned back to the method that had worked: serum therapy.
The problem was that antitoxin had been built for toxins, not for bacteria themselves. Researchers at the Pasteur Institute (restructured after 1928 to focus on serum therapy) began experimenting with hyperimmunizing animals not against isolated toxins but against whole bacterial cells. The logic was straightforward: train the animal immune system to recognize a pathogen, harvest the antibodies, inject them into a patient. But the execution was difficult. Bacterial surfaces were complex, antibodies were fragile, and the dose required to overwhelm an active infection was often larger than an animal could produce.
References
- 1.The Rise of Serum Therapy: A Medical History]], Rothman, 1995, Oxford University Press, pp. 87-156
- 2.Archives of the Institute for the History of Bacteriology: Statistical Methods and Clinical Trial Records]], Berlin Institute, 1956-present, call number HB-7834
- 3.The Halloway-Umezaki Legacy in European Archives]], Cambridge Centre Archives, 1974-1982
- 4.Müller et al]], Chemical Production and the Sulfonamide Era, 1991, Springer, pp. 234-267
- 5.The Immunology of Bacterial Toxins: Mechanisms and Clinical Application]], Weatherall, 1989, Cambridge University Press, pp. 301-342